Transition bias, an overabundance of transitions relative to transversions, has been widely 15 reported among studies of mutations spreading under relaxed selection. However, demonstrating 16 the role of transition bias in adaptive evolution remains challenging. We addressed this challenge 17 by analyzing adaptive antibiotic-resistance mutations in the major human pathogen 18 Mycobacterium tuberculosis. We found strong evidence for transition bias in two independently 19 curated datasets comprising 152 and 208 antibiotic resistance mutations. This was true at the level 20 of mutational paths (distinct, adaptive DNA sequence changes) and events (individual instances 21 of the adaptive DNA sequence changes), and across different genes and gene promoters 22 conferring resistance to a diversity of antibiotics. It was also true for mutations that do not code 23 for amino acid changes (in gene promoters and the ribosmal gene rrs), and for mutations that are 24 synonymous to each other and are therefore likely to have similar fitness effects, suggesting that 25 transition bias can be caused by a bias in mutation supply. These results point to a central role for 26 transition bias in determining which mutations drive adaptive antibiotic resistance evolution in a 27 key pathogen. 28 29 Keywords 30 Antibiotic resistance, evolution, mutation bias, Mycobacterium tuberculosis, transition bias 31 32 33 Significance statement 34 Whether and how transition bias influences adaptive evolution remain open questions. We 35 studied 296 DNA mutations that confer antibiotic resistance to the human pathogen 36
Introduction
We studied transition bias by calculating the ratio of the number of transitions to the number of 136 transversions in each dataset, separately for mutational paths and events. We calculated 95% 137 binomial confidence intervals on this ratio and an empirical p-value that describes the probability 138 of observing a transition:transversion ratio greater than the observed ratio, given a null model 139 (Materials and Methods). Among several null models described by Stoltzfus and McCandlish 
140
(11), we chose the most conservative, which assumes that all nucleotide mutations are equally 141 likely and there is no difference between the average fitness effects of transitions and 142 transversions. This null model gives a transition:transversion ratio of 0.5, because for any given 143 nucleotide there is one possible transition and two possible transversions. We therefore inferred 144 transition bias in cases where the lower bound of the 95% binomial confidence interval of the 145 observed transition:transversion ratio was greater than 0.5 and the empirical p-value was less than 146 0.05.
148
We observed transition bias in both mutational paths and mutational events, for both the Basel 149 and Manson datasets (Figure 1 ). Transition bias was considerably more pronounced in the 150 number of mutational events, as compared to the number of mutational paths. This provides 151 compelling evidence that transition bias influences the evolution of antibiotic resistance in MTB.
152
To understand why, assume there was no mutation-based or selection-based transition bias and 153 the high transition:transversion ratio at the level of mutational paths was instead due to chance, 154 such as a sampling artifact. In this scenario we would expect at most the same transition bias at 155 the level of events, rather than the roughly two-fold increase that we observed.
157
To determine which mutations explained the observed transition bias, we calculated the relative 158 rates of all six possible nucleotide pair mutations, accounting for GC content (1), which is 159 relatively high in MTB compared to other bacteria (Materials and Methods). For mutational 160 paths, the rate of A/T > G/C transitions exceeded the rate of any other nucleotide-pair mutation (Figure 2A,B) . The same was true for mutational events (Figure 2C,D) , where the rates of both 162 forms of transitions (G/C > A/T and A/T > G/C) were at least 1.5 times that of all forms of 163 transversions.
165
Because the influence of transition bias might depend on the mechanism of antibiotic resistance, 166 we next tested for transition bias separately for different antibiotics. This reduced the number of 167 mutational paths and events that could be analyzed, so we first determined the antibiotics for 168 which we had sufficient statistical power to ensure that an observed lack of transition bias was not 169 due to reduced sample size (Materials and Methods). This analysis revealed that, at the level of 170 mutational paths, our datasets were too small to test for transition bias of the strength observed in 171 the entire dataset for any individual antibiotic ( Figure S1A,B ). This is because at least 44 (Basel) 172 and 118 (Manson) mutational paths would be required to provide sufficient statistical power, and 173 the maximum number of paths per antibiotic was 30 (for streptomycin) in the Basel dataset and 174 51 (for rifampicin) in the Manson dataset ( Figure S2A,B) . In contrast, we were able to test for 175 transition bias in the mutational events associated with resistance to individual antibiotics, 176 because only 14 and 12 events were required to provide sufficient statistical power in the Basel 177 and Manson datasets (Figure S1C, D) . For this analysis, we considered mutations that 178 simultaneously conferred resistance to multiple antibiotics in separate categories. For example, 179 some mutations in the gene Rv1484 (inhA) and its promoter confer resistance to both isonazid 180 and ethionamide (5 and 6 mutations respectively in the Basel and Manson datasets). To avoid 181 counting such mutations multiple times, we analyzed them separately and did not include them 182 together with mutations that conferred resistance only to isonazid or ethionamide. All but two 183 individual antibiotics, both in the Basel dataset, had enough mutational events to test for 184 transition bias ( Figure S2C ,D).
186
We observed transition bias in the number of mutational events associated with the evolution of 187 resistance to almost all antibiotics, with transition bias indicated by transition:transversion ratios 188 ranging from 1.59 for pyrazinamide to 41.6 for kanamycin (i.e., from more than three-fold to 189 more than eighty-fold excess of the null expectation; Table 1 ). The glaring exception was 190 isoniazid, which was dominated by a single C > G transversion (S315T in KatG), representing 191 409 of the 472 mutational events associated with isoniazid resistance in the Basel dataset (or 671 192 events if we include mutations in inhA that are associated with resistance to both isoniazid and 193 ethionamide) and 321 of the 389 mutational events associated with isoniazid resistance in the
194
Manson dataset (or 545 if we include inhA).
196
The above results suggest transition bias influences the evolution of antibiotic resistance in MTB.
197
However, it remains unclear whether this bias is mutation-based or selection-based. To may nevertheless have variable fitness effects despite not encoding amino acid changes (21), and 212 we discuss this further below.
214
Second, we considered cases where different mutations caused the same resistance-conferring 215 amino acid change, and were therefore synonymous to each other and expected to have similar 216 fitness effects. Specifically, we considered amino acid changes that can be caused by both 217 transition and transversion mutations at the same ancestral codon. For example, methionine can 218 mutate to isoleucine via the transition ATG > ATA or the transversions ATG > ATT and ATG > 219 ATC. In the standard genetic code, there are five such amino acid changes ( Table 2 ). These were 220 rare or non-existent in the Basel and Manson datasets (Table 2) 
230
Ideally, we would have sufficient mutational paths or events to perform the above analysis on all 231 of the amino acid changes in Table 2 . To this end, we analyzed an older dataset, TBDReaMDB 232 (22) , that included a greater number of resistance mutations, but was not compiled with the same 233 strict inclusion criteria as the Basel and Manson datasets. Across the 717 mutational paths from 234 this dataset that we included (Materials & Methods), we observed transition bias 235 (transition:transversion ratio of 0.86; 95% binomial confidence interval: (0.74, 1.00); empirical p-236 value = 0). In this dataset there were also a sufficient number of the amino acid changes shown in Table 2 to take an aggregated approach to calculating transition bias amongst mutations that are 238 synonymous to each other. Specifically, amongst all such mutational paths, there were 16 239 transitions and 12 transversions ( Table 2 ; transition:transversion ratio of 1.33; empirical p-value = 240 0.014). This was more than twice the expected ratio of 0.63, derived from a null model 241 accounting for the number of transitions and transversions in these particular mutational paths 242 (Materials and Methods).
244

Discussion
245
We found strong transition bias at multiple levels (mutational paths and events) and in multiple 246 independently curated datasets (Basel, Manson, and TBDReamDB). By analyzing antibiotic 247 resistance mutations that confer a fitness benefit in the presence of selecting antibiotics, we 248 overcame the difficulty of classifying mutations as adaptive. By focusing part of our analysis on 249 nucleotide substitutions in gene promoters and the ribosomal gene rrs, and on mutations that are 250 synonymous to each other, we overcame the difficulty of ruling out an overabundance of 251 transitions caused by transitions and transversions encoding amino acid changes with different 252 average fitness effects. Our data also revealed notable exceptions to the general trend toward 253 transition bias. In particular, the most common resistance mutation by far against isoniazid was a 254 transversion. Our results have four key implications for antibiotic resistance evolution and 255 mutational biases.
257
First, quantifying the overabundance of transitions improves our ability to predict mutational 258 pathways to resistance. MTB often acquires multiple resistance mutations sequentially, and some 259 mutational trajectories are more common than others (23). Our results suggest the probability of 260 following a given trajectory will be higher when it contains a greater fraction of transitions than 261 alternative trajectories encoding similar resistance phenotypes.
262
Second, for at least part of our data, we excluded an important potential explanation for transition 264 bias, specifically that transitions encode amino acid changes with different average fitness effects 265 than transversions. We did this by showing that the bias extended to mutations in gene promoters 266 and the ribosomal gene rrs, and to mutations that are synonymous to each other. We still cannot 267 rule out variable fitness effects that are not linked to amino acid changes, as observed for 268 streptomycin-resistance mutations in ribosomal genes (21) 
280
Third, if we then accept that a biased mutation supply explains at least some of the observed bias 281 among mutational paths to resistance, this is consistent with a role for mutation-limited 'first-282 come-first-served' dynamics (17) 
287
which is less supportive of mutation-limited dynamics. The extent to which such lineages 288 compete with each other will depend on the spatial population structure, for example if they are in different lung sections they may not compete directly (28). Overall, this indicates resistance may 290 evolve via a process somewhere along a continuum between first-come-first-served and pick-the-291 winner (29).
293
Fourth, MTB may be closer to one end of this continuum when challenged with some antibiotics 294 than others. Specifically, a single transversion accounted for >70% of the mutational events 295 conferring isoniazid resistance (the same was also true of mutations conferring resistance to both 296 isoniazid and ethionamide), indicating a greatly reduced role for transition bias. Instead, the high 297 frequency of the S315T mutation in katG among isoniazid-resistant isolates may reflect that it 298 confers resistance to clinically relevant concentrations, particularly in combination with inhA 299 promoter mutations (30), without severely reducing catalytic function (20). MTB strains carrying 300 this mutation, while not detected in in vitro mutant screens (31), also appear more likely to 301 transmit than strains with other isoniazid-resistance mutations (32).
303
Our observation that transition bias is prevalent at the level of paths, but even stronger at the level 304 of events, is consistent with Stoltzfus & McCandlish's (2017) observations for mutations in 305 parallel experimental or natural populations, and is expected under mutation-based transition bias 306 when the sample size is large (11). Specifically, when the sample size is small, each observed 307 mutational path is represented by one event only, so the transition:transversion ratio of paths and 308 events is identical. With increasing sample size, individual paths are represented by multiple 309 events. In this case, the transition:transversion ratio among events will tend toward that of the 310 adaptive mutation rate, and transitions will be overrepresented if there is mutation-based 311 transition bias. However the transition:transversion ratio of observed paths will tend toward the 312 ratio for all possible unique adaptive mutations, which would approximate 0.5 even when there is 313 mutation-based transition bias (11). Note the observed ratio at the level of paths, while weaker 314 than at the level of events, still exceeded 0.5. This could be because our datasets are incomplete samples of the possible paths to resistance in MTB, and the likelihood of a given path featuring in 316 our datasets is higher if it occurs more frequently (i.e. mutation-based bias and intermediate 317 sample size). Alternatively, our datasets may capture the vast majority of paths to resistance, but 318 due to selection-based bias a greater fraction of them are transitions than transversions.
320
The bias we observed was also prevalent at the level of individual nucleotide changes, with A/T > 
333
In conclusion, our data support the hypothesis that a bias toward transitions plays a key role in 334 determining the genetic changes driving antibiotic resistance evolution.
336
Materials and Methods
337
The Basel dataset
338
We curated a list of mutations known to confer resistance to one or more of the following drugs 339 or drug classes: isoniazid, ethionamide, rifampicin, ethambutol, pyrazinamide, fluoroquinolones, excluded mutations in rpsA and ahpC, because these genes were unlikely to confer resistance to 342 pyrazinamide and isoniazid respectively (36, 37) . We then added gyrB to the list of pertinent 343 genes, because some mutations in this gene have been shown to lead to fluoroquinolone 344 resistance (38).
346
We included additional mutations if they met one or more of the following criteria: 1) they have 347 been shown, by virtue of allelic exchange, to confer resistance; 2) introduction of the mutation 348 into the enzyme of interest was investigated in vitro and shown to confer properties consistent 349 with drug resistance; 3) they were identified in laboratory-generated antibiotic-resistant strains as 350 the most likely candidate for resistance; or 4) there was a clear correlation between the presence 351 of the mutation and drug resistance as detected by phenotypic drug susceptibility testing of 352 clinical strains. This resulted in a list of 196 mutations (Table S1 ), of which we found 152 in at 353 least one of 9,351 publicly-available MTB genomes (Table S2 ) (39). These are the mutational 354 paths in the Basel dataset (Table S3 ).
356
We determined the mutational events by first calling single nucleotide polymorphisms in the 357 9,351 genomes and then using the polymorphisms to reconstruct the genomes' phylogeny and to 358 infer mutational gains and losses throughout the phylogeny, as follows. We clipped Illumina 
371
Genomes were excluded if 1) they had an average coverage < 20x, 2) more than 50% of their 372 single nucleotide polymorphisms were excluded due to the strand bias filter, 3) more than 50% of 373 their single nucleotide polymorphisms had a percentage of reads supporting the call between 10% 374 and 90%, or 4) they contained single nucleotide polymorphisms that belong to different MTB 375 lineages, because this indicates that a mix of genomes was sequenced. Finally, we excluded all 376 genomic positions with more than 10% missing data. This resulted in a final dataset of 300,583 377 polymorphic positions.
379
We inferred a phylogenetic tree based on the 300,583 single nucleotide polymorphisms with 380 FastTree (46), using double digit precision and the options -nocat and -nosupport. We extracted Table 4 in ref (19)), and searched for these polymorphisms in 5,310 (19)). We filtered these polymorphisms to only include point mutations, resulting in 394 a dataset of 208 mutational paths. Manson et al. (19) calculated the number of events per 395 mutational path by reconstructing the phylogeny of the 5,310 MTB genomes and using a 396 parsimony-based analysis to determine mutational gains and losses throughout the phylogeny. We 397 used their estimates of the number of events per mutational path, as they were reported in 398 Supplementary 
400
The TBDReaMDB dataset 401 TBDReaMDB is a dataset of 1,178 mutational paths associated with resistance to at least one of 9 402 antibiotics. We filtered this dataset to only include mutational paths that (1) 
409
We used this dataset, which includes a greater number of mutations than the Basel and Manson 410 datasets, but with less strict inclusion criteria, to study transition bias amongst amino acid 411 changes that can be caused by mutational paths that are transitions or transversions, and that arise 412 from the same codon (Table 2) Table 2 ). Some are observed multiple times (at different loci),
418
giving a total of 28 such observations (i.e., the sum of the values in the rightmost column of Table  2 ). The expected probability of a transition under the null model is (1/ ! )
where q i is the number of times each mutation (path) is observed at different loci 421 (events). For the m = 6 observed mutational paths, this gives a null transition probability of
422
(1/(1+1+11+1+7+7))*(1*0.5 + 1*0.5 + 11*0.33 + 1*0.33 + 7*0.33 + 7*0.5) = 0.385, which 423 equates to a transition:transversion ratio of 0.63.
425
Calculating empirical p-values for transition:transversion ratios
426
To calculate an empirical p-value for an observed transition:transversion ratio in a dataset 427 containing x mutational paths or events, we randomly generated 10 6 datasets of x mutations 428 according to our null model that transversions are twice as likely as transitions. Each of the x 429 mutations in each dataset was chosen to be a transition with probability 1/3 or a transversion with 430 probability 2/3 (when we analyzed mutations that are synonymous to each other in the 431 TBDReaMDB dataset, we used probabilities of 0.385 and 0.615). We determined the 432 transition:transversion ratio for each of these datasets and then calculated the empirical p-value as 433 the fraction of these ratios that were greater than the observed ratio.
435
Calculating the relative rates of the six nuleotide pair mutations 436 GC content may influence the number of mutational paths or mutational events in our datasets.
437
MTB has a high GC content, 65.6% genome-wide (48) and 64.4% in the 17 genes associated with 438 resistance in the Basel and Manson datasets. Thus, we expected to see more mutations from G/C 439 or C/G than from A/T or T/A, simply because there are more Gs and Cs in the genes associated 440 with resistance in our datasets. To control for this effect in our calculation of the relative rates of 441 the six possible nucleotide pair mutations, we followed the method of Hershberg and Petrov (1) .
442
Specifically, we first determined the number of mutations of each type we would expect under The numbers of paths and events are much smaller for individual antibiotics than in the full 450 datasets, which may render our test of transition bias statistically underpowered for individual 451 antibiotics. To determine the minumum number of mutational paths or events required to rule out 452 the possibility that an observed lack of transition bias might be due to small sample size, we 453 downsampled our datasets as follows. For each of the Basel and Manson datasets separately, we 454 randomly sampled x mutational paths or events from the dataset without replacement and 455 calculated the fraction of these paths or events that were transitions (we calculate this fraction, 456 rather than the transition:transversion ratio, to avoid division by zero) and the associated 95% 457 binomial confidence interval. We repeated this 10 4 times for each value of x, and calculated the 458 average fraction of transitions, the minimum of the lower 95% confidence intervals, and the 459 maximum of the upper 95% confidence intervals. For mutational paths, we varied x from 2 to the 460 maximum number of mutational paths in each dataset, and for mutational events, we varied x 461 from 2 to 800. We then determined the minimum value of x for which the minimum of the 95% 462 confidence intervals exceeded 1/3, which is the expected fraction of transitions under the null 463 model (corresponding to a transition:transversion ratio of 0.5). This is the minimum number of 464 mutational paths or events required to exclude the possibility that an observed lack of transition 465 bias at a given value of x is due to small sample size, given the transition bias in the full dataset.
466
For the Basel dataset, this minimum number of mutational paths was 44 and the minimum 467 number of mutational events was 14. In the Manson dataset, the minimum number of mutational 468 paths was 118 and the minimum number of mutational events was 12. No antibiotic was 469 associated with more than these minimum numbers of mutational paths in either the Basel or events for all antibiotics and combinations except for Amikacin+Capreomycin, and mutations 472 conferring resistance only to Capreomycin in the Basel dataset ( Figure S2C,D) . 
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